SCHEMBL3701006

SCHEMBL3701006

Cc1cnc2c(-c3ccc(Cl)c(C)c3)c(NC(=O)CCc3ccccc3)nn2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 6/20 0.57
KCNQ2 O43526 6/20 0.57
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
WNT1 P04628 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
MLYCD O95822 1/20 0.41
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.40
F2 P00734 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700999 0.94 KCNQ3 (0.54) KCNQ3KCNQ2MEN1KMT2ASMN1; SMN2
SCHEMBL3706348 0.83 MLYCD (0.53) KCNQ3KCNQ2MLYCDPOLBHCAR2
SCHEMBL3703282 0.81 KCNQ3 (0.56) KCNQ3KCNQ2MEN1KMT2ASMN1; SMN2
SCHEMBL3700928 0.76 KCNQ3 (0.72) KCNQ3KCNQ2RAB9A
SCHEMBL3706860 0.76 MAPK14 (0.56) KCNQ3KCNQ2MEN1KMT2ASMN1; SMN2
SCHEMBL3696279 0.76 KCNQ3 (0.52) KCNQ3KCNQ2MEN1KMT2ASMN1; SMN2
SCHEMBL3707506 0.76 KCNQ3 (0.84) KCNQ3KCNQ2
SCHEMBL3703621 0.75 KCNQ3 (0.58) KCNQ3KCNQ2SMN1; SMN2LMNAGSK3B
SCHEMBL3712494 0.75 KCNQ3 (0.81) KCNQ3KCNQ2
SCHEMBL3696361 0.72 KCNQ3 (0.73) KCNQ3KCNQ2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 KCNQ3 4/4885KCNQ2 2/4885MEN1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.